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SUMMARY
There is ongoing debate regarding the effectiveness of
antidepressants in patients with milder major depressive
disorder (MDD). This post-hoc analysis evaluated the
efficacy and tolerability of duloxetine in the subset of 159
(75 duloxetine and 84 placebo) patients with milder MDD
(baseline HAMD17 total score  15 and  18) who were
treated once daily with duloxetine 60 mg or placebo in two
identical, 9-week, randomised, double-blind trials. At end-
point, change from baseline on HAMD17 was greater in
the duloxetine group ( 7.0) than in the placebo group
( 4.1) (p ¼ 0.005). Response and remission rates, and
improvement on the Clinical Global Impressions-Severity
(CGI-S) scale, the Patient Global Impressions-
Improvement (PGI-I) scale, and measures of painful symp-
toms were also significantly better in the duloxetine group
(p < 0.05). Tolerability was consistent with that seen in
previous studies of duloxetine in patients with more severe
depression. In conclusion, duloxetine 60 mg/day is effec-
tive and well tolerated in milder MDD.
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INTRODUCTION
Considerable evidence supports the efficacy of antidepressants
in the treatment of moderate and severe major depressive
disorder (MDD), yet there are relatively few data to support
the use of newer antidepressants in treating patients with
milder MDD (1,2). It has been suggested that antidepressants
should not be used for the initial treatment of mild depres-
sion, because the risk/benefit ratio is unfavourable (3). As
many patients presenting with MDD in the primary care
setting have milder disease (4), there is a need to more closely
examine the efficacy, safety and tolerability of antidepressant
treatment in patients with milder MDD.
Attempts to draw conclusionsa b o u tt h eu s e f u l n e s so f
antidepressants in milder MDD are hampered by incon-
sistencies in the terminology used to describe disease and
disease severity. The term ‘mild depression’ has been used
by commentators and investigators to describe a number of
different disease states. Whereas MDD is characterised by
relatively well-defined, accepted and recognised criteria [i.e.
Diagnostic and statistical manual of mental disorders
(DSM-IV-TR) (5), Research Diagnostic Criteria (RDC) (6)],
the term ‘mild depression’ means different things to different
people. This term has been interpreted to mean minor
depressive disorder, subsyndromal depression, dysthymia
and other states, all of which are diagnostic entities in
their own right; these entities differ from MDD in that
they are characterised by fewer symptoms, different dura-
tions and lower functional impact than MDD (7–10). The
term milder depression has also been used to refer to
milder cases of depression that meet the diagnostic criteria
f o rM D Db u th a v ef e w ,i fa n y ,s y m p t o m sb e y o n dt h e
minimum required and result in only minor functional
impairment (5). In clinical practice, where few physicians
use a structured clinical interview when making a clinical
diagnosis, some patients are diagnosed with MDD even
though they do not meet the full diagnostic criteria (11).
Despite the disability associated with milder depressive
states (8,12,13), some treatment guidelines maintain that
treatment with antidepressants in such cases may be associated
with a poor risk–benefit ratio and that this precludes recom-
mending the use of antidepressants in such circumstances (3).
In the past, the substantial side effects associated with the
tricyclic antidepressants (TCAs) may have justified such a
recommendation. However, with the advent of newer anti-
depressants with efficacy similar to that of the TCAs but with
considerably better tolerability (14,15), the risk/benefit ratio
of antidepressant treatment is arguably now improved. In
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milder MDD with antidepressants should be revisited.
Duloxetine hydrochloride (Cymbalta
 ) is a dual inhibitor
of serotonin (5HT) and norepinephrine (NE) reuptake. It has
a high and relatively balanced (i.e. ratio of binding affinities)
affinity for 5HT and NE reuptake transporters (16,17).
Moreover, duloxetine has negligible affinity for muscarinic,
cholinergic, histamine1 and other receptors (16,18).
Duloxetine has been shown to be an effective treatment for
MDD at doses ranging from 40 to 120 mg daily (19–22),
including cases of severe depression (23). Duloxetine is licensed
for the treatment of MDD in the US at a daily dose of
40–60 mg, and in Europe and elsewhere at a daily dose of
60 mg, the dose received by the patients in this analysis.
We performed post-hoc analyses of pooled data to evaluate
the efficacy and tolerability of duloxetine 60 mg once daily in
patients who met the criteria for MDD but whose depression
was of milder severity as defined by a baseline total score of
15–18, inclusive, on the 17-item Hamilton Depression
Rating Scale (HAMD17) (24,25).
METHODS
Study Design
This analysis combined data from two identical, 9-week,
randomised, multicentre, double-blind, placebo-controlled,
parallel-group Phase III trials in adults with MDD (19,20).
The study design included double-blind variable-duration
placebo lead-in and lead-out periods to blind the patients
and investigators to the beginning and end of active treat-
ment. Patients received placebo or duloxetine 60 mg daily for
up to 9 weeks. Both studies were performed according to the
Declaration of Helsinki and approved by the appropriate
ethics committees. All patients gave written informed consent.
Further details regarding study design, patients and methods
are described elsewhere (19,20).
Patients
The two studies enrolled 245 and 267 patients, respectively,
across 39 centres in the US. Patients were male or female
adults at least 18 years of age who met the diagnostic criteria
for MDD as defined in the DSM-IV (26), based on the Mini
International Neuropsychiatric Interview (MINI) (27). Site
personnel administering the MINI were required to have had
substantial previous experience using either this instrument or
the SCID (28). To be enrolled in these studies, patients were
required to score  15 on the HAMD17 (24,25) and  4o n
the Clinical Global Impressions-Severity (CGI-S) scale (29) at
screening and before the start of treatment.
Patients were excluded from the studies if they had a
current Axis I disorder other than MDD, including but not
limited to dysthymia; an anxiety disorder as a primary diag-
nosis within a year of study entry; or an Axis II disorder that
could interfere with compliance with the study protocol.
Patients were also excluded if they had a serious medical
illness, a history of substance abuse or dependence within a
year of study entry, or a positive urine drug screen. Additional
exclusion criteria included a lack of response of the current
depressive episode to two or more adequate courses of anti-
depressant therapy, treatment-resistant depression, initiation
or stoppage of psychotherapy within 6 weeks before enrol-
ment or starting psychotherapy at any time during the study.
Concomitant medications with primarily central nervous sys-
tem activity were not permitted, with the exception of chloral
hydrate (up to 1000 mg) or zolpidem (up to 10 mg) for
insomnia for no more than six nights during the study.
Measurements
Patients were evaluated at a screening visit approximately 1
week before the start of treatment, at the start of treatment
(week 0), once a week for the first 3 weeks of active treatment
and every other week thereafter. The primary efficacy mea-
surement was the HAMD17 total score. Response and remis-
sion rates based on the HAMD17 were secondary efficacy
measures. Response was defined as a decrease from baseline
to endpoint of  50% on the HAMD17 total score. Remission
was defined as an endpoint HAMD17 total score  7.
Additional secondary efficacy measurements included the
physician-assessed CGI-S scale (29), the Patient Global
Impression-Improvement (PGI-I) scale (29) and the Somatic
Symptom Inventory (SSI) (30). Severity of overall pain,
shoulder pain, back pain, headache, pain while awake,
and daily interference due to pain were measured via visual
analogue scales (VAS) (31).
Safety and tolerability assessments were performed at each
visit and included spontaneously reported adverse events,
serious adverse events, and measurement of supine blood
pressure and heart rate. Tolerability was also assessed through
comparisons of rates of discontinuation due to adverse events.
Sustained elevation in blood pressure was defined as supine
diastolic blood pressure of  90 mmHg with an increase from
baseline of 10 mmHg or supine systolic blood pressure of
 140 mmHg with an increase from baseline of 10 mmHg
for at least three consecutive visits.
Statistical Analysis
All randomised patients with milder MDD, defined as an
HAMD17 score of 15–18, inclusive, at baseline, were
included in the safety analysis, while patients with milder
MDD and at least one postbaseline assessment were included
in the efficacy analysis, as required to determine change from
baseline. Baseline was defined as the most recent observation
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the last, postbaseline observation obtained during the 9-week
treatment period.
Differences between the treatment groups in the change
from baseline to endpoint in continuous variables were
assessed using an analysis of covariance (ANCOVA) model
which included the main effects for treatment group and
study, with baseline value included as a covariate.
Comparisons were based on least squares adjusted mean
change. Categorical outcomes were assessed using the
Cochran-Mantel-Haenszel test for general association or
Fisher exact test when cell sizes were very small.
Adjustments for multiple comparisons were not made, and
missing data were not imputed. Statistical significance was
determined at the p < 0.05 level. Consistent with the proto-
cols for the individual studies, the primary outcome for
assessing efficacy in this work was the change from baseline
in HAMD17 total score. Additional efficacy outcomes are
presented as supportive evidence. Change from baseline was
evaluated using the approach of last observation carried for-
ward (LOCF) for all patients with at least one postbaseline
observation.
To assess the consistency of the treatment response across
the population, we performed linear regression on the change
in HAMD17 total score and logistic regression on response
and remission rates. Consistency of treatment effect was
assessed via the baseline HAMD17 score-by-treatment group
interaction. Models included terms for treatment group,
study and baseline score, and interactions were considered
statistically significant at the p < 0.10 level.
RESULTS
Demographics and Disposition
A total of 159 (84 placebo and 75 duloxetine) patients had
milder MDD as defined by a score of 15–18, inclusive, on the
HAMD17 at baseline, and were included in the safety analysis;
153 patients (82 placebo and 71 duloxetine) had at least one
postrandomisation visit and were included in the efficacy
analyses. The treatment groups were similar with respect to
demographic characteristics and depression history (Table 1).
The mean HAMD17 scores at baseline were 16.9 for the
placebo group and 16.7 for the duloxetine group.
Efficacy
Patients in the duloxetine group had significantly greater
improvement in HAMD17 total scores compared with
patients in the placebo group ( 7.0 vs.  4.1, p ¼ 0.005)
(Table 2). Response and remission rates were also signifi-
cantly higher among duloxetine-treated patients compared
with placebo-treated patients. The rate of remission in the
duloxetine group was 40.8%, compared with 24.4% in the
placebo group (p ¼ 0.037), and the rate of response in the
duloxetine group was 47.9%, compared with 29.3% in the
placebo group (p ¼ 0.020).
The results of analyses of other secondary efficacy measures
were also indicative of greater improvement in duloxetine-
treated patients (Table 2). Global improvement was signifi-
cantly better in the duloxetine group compared with the
placebo group when assessed by both physicians (CGI-S)
and patients (PGI-I). When patients rated their pain severity
using VAS, improvement was similar in the duloxetine and
placebo groups for four of the six measures (headache,
shoulder pain, interference with daily activities and time in
Table 1 Baseline demographics and depression history of patients
with milder major depressive disorder (MDD)
Characteristic
Placebo
(n ¼ 84)
Duloxetine
60 mg (n ¼ 75) p-value*
Age (years)
Mean (SD) 41.8 (15.7) 39.6 (13.1) 0.687
Range 18–82 19–75
Sex (%)
Female 52 (61.9) 48 (64.0) 0.870
Origin (%)
Caucasian 68 (81.0) 61 (81.3) 0.257
African descent 7 (8.3) 8 (10.7)
Hispanic 8 (9.5) 3 (4.0)
Other 1 (1.2) 3 (4.0)
Weight (kg)
Mean (SD) 82.5 (19.8) 86.0 (27.4) 0.327
Range 49.9–131.7 46.3–168.9
HAMD17 total
Mean (SD) 16.9 (1.1) 16.7 (1.0) 0.056
Median 17 17
Range 15–18 15–18
CGI-S
Mean (SD) 4.1 (0.3) 4.1 (0.2) 0.511
Range 4–5 4–5
Age at first
depressive episode
Mean (SD) 28.8 (15.6) 28.2 (13.2) 0.953
Range 5–72 6–69
Duration of current
depressive episode (weeks)
Mean (SD) 108.0 (310.7) 116.8 (202.1) 0.619
Range 2–2392 3–1211
Number of previous
depressive episodes
Mean (SD) 5.8 (16.8) 5.4 (16.5) 0.903
Range 0–141 0–99
CGI-S, Clinical Global Impressions-Severity; HAMD17, 17-item Hamilton
Depression Rating Scale; SD, standard deviation. *The p-values for contin-
uous measures are based on a main effects ANOVA model including treatment
and study. The p-values for categorical outcomes are based on the Cochran-
Mantel-Haenszel test for general association controlling for study.
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duloxetine with regard to reductions in both overall pain and
back pain.
Regression results demonstrated a consistency in the treat-
ment effect across this population with regard to both change
in HAMD17 total score (p ¼ 0.513) and remission rates
(p ¼ 0.179). For response rates, duloxetine–placebo differ-
ences tended to decrease with increasing baseline HAMD17
score within the population studied (p ¼ 0.087).
Safety
Four (4.8%) patients in the placebo group and 10 (13.3%) in
the duloxetine group discontinued the study because of
adverse events (p ¼ 0.090). The adverse events that led to
discontinuation were different for each of the 14 patients who
discontinued and included ataxia, mania, somnolence and
vomiting in the placebo group, and anorexia, anorgasmia,
central nervous system stimulation, delayed ejaculation, fati-
gue, hypertension, insomnia, migraine, nausea and rash in the
duloxetine group. Treatment-emergent adverse events
reported in 5% or more of duloxetine-treated patients are
listed in Table 3. Treatment-emergent adverse events were
noted in 61 (72.6%) patients in the placebo group, compared
with 70 (93.3%) in the duloxetine group (p < 0.001). The
most commonly reported treatment-emergent adverse events
among duloxetine-treated patients were nausea (34.7%), dry
mouth (22.7%), headache (20.0%) and dizziness (18.7%),
and except for headache, these were reported significantly
more often than in the placebo group (p   0.006). No
serious adverse events were reported by any patients included
in this analysis.
Adverse events occurring within 2 weeks of abrupt dis-
continuation of treatment were reported in 9 (16.1%)
patients in the placebo group, compared with 19 (41.3%)
in the duloxetine group (p ¼ 0.005). The discontinuation-
emergent adverse events most commonly reported in
duloxetine-treated patients were dizziness (15.2 vs. 0% for
placebo) and nausea (6.5 vs. 0% for placebo), and only
dizziness occurred in significantly more duloxetine-treated
patients than in placebo-treated patients (p ¼ 0.003).
Table 2 Summary of primary and secondary efficacy measures for patients with milder major depressive disorder (MDD)
Placebo (n ¼ 82) Duloxetine 60 mg (n ¼ 71)
Measure Baseline* Change† Baseline* Change† p-value‡
HAMD17 total 16.9  4.1 16.7  7.0 0.005
CGI-S 4.1  0.9 4.0  1.4 0.010
PGI-I – 3.4 – 2.7 <0.001
VAS
Overall 22.2  3.5 23.7  9.9 0.045
Headache 15.9  1.7 13.6  1.1 0.854
Back pain 17.6  2.3 19.3  9.2 0.024
Shoulder pain 13.8  3.9 14.5  6.9 0.243
Interference with daily activities 14.1  1.6 13.7  3.7 0.443
Time in pain while awake 27.4  6.6 29.3  10.7 0.272
SSIavg
§ 1.7  0.2 1.7  0.3 0.042
SSIpain
{ 12.9  1.4 12.7  2.3 0.075
CGI-S, Clinical Global Impressions-Severity of Illness; HAMD17, 17-item Hamilton Depression Rating Scale; PGI-I, Patient Global Impressions-Improvement;
SSI, Somatic Symptom Inventory; VAS, Visual Analogue Scale for pain. *Mean baseline values. †Least-squares mean change from baseline to last observation.
‡Pairwise comparisons between duloxetine and placebo. §The SSIavg is the average score for all items on the SSI28, a 28-item questionnaire on which patients
indicate how much various physical complaints (including pain in joints and pain in neck) bothered them over the past week using a rating scale of 1 (not at all)
to 5 (a great deal) (30). {The SSIpain is the sum of the seven pain-related items (items 2, 3, 9, 14, 19, 27 and 28) of the SSI28 (30).
Table 3 Number (%) of patients with milder major depressive
disorder (MDD) who reported treatment-emergent adverse events*
Event
Placebo
(n ¼ 84)
Duloxetine
60 mg (n ¼ 75) p-value
Nausea 6 (7.1) 26 (34.7) <0.001
Dry mouth 6 (7.1) 17 (22.7) 0.006
Headache 20 (23.8) 15 (20.0) 0.574
Dizziness 4 (4.8) 14 (18.7) 0.006
Appetite decreased 2 (2.4) 10 (13.3) 0.010
Constipation 3 (3.6) 10 (13.3) 0.026
Insomnia 10 (11.9) 9 (12.0) 0.981
Somnolence 7 (8.3) 8 (10.7) 0.616
Vomiting 2 (2.4) 8 (10.7) 0.032
Diarrhoea 5 (6.0) 7 (9.3) 0.429
Fatigue 3 (3.6) 7 (9.3) 0.137
Pharyngitis 6 (7.1) 7 (9.3) 0.619
Upper respiratory
tract infection
4 (4.8) 7 (9.3) 0.262
Back pain 2 (2.4) 5 (6.7) 0.183
Dyspepsia 8 (9.5) 4 (5.3) 0.323
*Events included in the table are those reported in  5% of duloxetine-treated
patients.
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signs were modest and clinically unremarkable in both treat-
ment groups (Table 4). Although the difference in the mean
change in heart rate between the duloxetine and placebo
groups was statistically significant, it was not considered
clinically meaningful as none of the changes in heart rate
resulted in patients’ discontinuing the study and none met
the criteria for a serious adverse event. No patients exhibited
any treatment-emergent sustained elevations in blood
pressure.
DISCUSSION
In this pooled analysis, duloxetine 60 mg once daily was
significantly better than placebo in reducing the severity of
depressive symptoms in patients with milder MDD. Decrease
from baseline in the total HAMD17 score, the primary effi-
cacy variable, was significantly greater in the duloxetine group
than in the placebo group. Improvement from baseline was
also significantly greater in the duloxetine group than in the
placebo group on most of the secondary measures, including
response and remission rates, the CGI-S, PGI-I, SSI, and
the VAS assessments of overall pain and back pain.
Duloxetine-associated efficacy, as measured by the HAMD17
(the primary efficacy variable) and remission rates, remained
consistent across the narrow range of baseline HAMD17
scores that defines this population, although there was an
unexpected tendency for the treatment effect seen in response
rates to decrease as baseline HAMD17 scores increased. This
finding is likely to be an artefact given the lack of a similar
finding for HAMD17 mean change or remission rate.
In terms of safety and tolerability, more duloxetine-treated
patients than placebo-treated patients discontinued treatment
because of an adverse event, although the difference was not
statistically significant. Nevertheless, the rate of discontinua-
tion due to adverse events in these mildly depressed patients
(13.3%) was similar to that seen in the two studies from
which the subset of patients with milder MDD included in
this analysis was taken [13.8% (19), 12.5% (20)]. Some
adverse events were reported more frequently by duloxetine-
treated patients than by placebo-treated patients. Significantly
more duloxetine-treated than placebo-treated patients
reported adverse events after abrupt discontinuation of treat-
ment. The frequency of discontinuation-emergent adverse
events might have been lower had doses been reduced gradu-
ally, as directed in the product labelling. No serious adverse
events were reported in either treatment group, and the
magnitude of observed changes in weight and vital signs was
not considered to be clinically significant.
The results of the efficacy and tolerability analyses pre-
sented here, including the nature and frequency of treat-
ment-emergent adverse events, in patients with milder
MDD are consistent with findings published previously on
the efficacy and tolerability of duloxetine in MDD across
broader populations of depressed patients (19–22,32). There
is a perception that patients with milder depression might be
more intolerant of adverse events when treated with antide-
pressants, a belief which has contributed to concerns that the
benefits of antidepressant treatment in patients with milder
disease may not outweigh the possible risks, but our findings
do not support this.
Findings from our analyses are consistent with those from a
number of published studies, although differences in the
definition of mild depression and consequent variations in
the nature of populations studied make direct comparison
difficult. Paykel et al. (4) assessed the benefits of amitriptyline
in 141 primary care patients, many of whom had milder
depression on the basis of their baseline HAMD17 score.
The patients studied satisfied the Research Diagnostic
Criteria (RDC) for probable or definite major, minor, or
intermittent depression (6) and had baseline HAMD17 scores
from 6 to 24. They received double-blind treatment with
amitriptyline (median dose 125 mg) or placebo daily for 4–
6 weeks. The authors found that amitriptyline-treated
patients with baseline HAMD17 scores from 13 to 24 derived
benefit from treatment, whereas those with scores of 6–12 did
not (4). They concluded that amitriptyline treatment is ben-
eficial in all but the most mildly depressed patients. These
results are similar to those of Stewart et al. (33). Stewart and
colleagues also studied outpatients who met the RDC for
Table 4 Least squares mean change from baseline in weight and vital signs in patients with milder major depressive disorder (MDD) treated
with placebo or duloxetine 60 mg once daily
Placebo Duloxetine
Variable n Mean change   SE n Mean change   SE p-value*
Body weight (kg) 82  0.5   0.31 71  0.5   0.34 0.954
Heart rate (bpm) 82  1.9   0.90 71 2.5   0.97 0.001
Systolic blood pressure (mmHg) 82  2.6   1.24 71  2.0   1.33 0.723
Diastolic blood pressure (mmHg) 82  0.2   1.00 71 1.0   1.07 0.412
bpm, beats per minute; mmHg, millimetres of mercury; SE, standard error.
*Between-group comparison based on ANCOVA model containing treatment, study and baseline value.
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baseline HAMD scores as a measure of pretreatment depres-
sion severity. They found that the response to desipramine
treatment was significantly greater than the response to pla-
cebo among patients with pretreatment HAMD scores from
14 to 18, but not among those with pretreatment HAMD
scores of <14.
The analysis populations studied by Paykel et al. and
Stewart et al. (4,33) differed from our analysis population in
that they included patients with minor depression and inter-
mittent depression in addition to MDD, whereas all patients
in our analyses were required to meet the DSM-IV criteria for
MDD. Data from studies of the effect of antidepressants in
patients with milder depression who met the RDC or DSM
criteria for MDD are sparse. Although the results of such
studies have been mixed, generally they are consistent with
our findings and those published by Paykel and Stewart. That
is, studies in which the populations consisted of MDD
patients with pretreatment HAMD scores greater than 13 or
14 demonstrated a significant benefit of pharmacotherapy,
whereas patients with pretreatment HAMD scores below
that cut-off did not (33–37). A study by Fabre and Putman
and a further study by Elkin et al. are exceptions to this
generalisation (38,39). These studies found no significant
differences in treatment outcomes between the placebo and
antidepressant treatment groups in patients who met criteria
for MDD and whose pretreatment HAMD scores were
between 14 and 19 or 20.
The disparity in the results of studies evaluating the treat-
ment of milder depressive states may be attributable to the
lack of consistent diagnostic criteria, sample heterogeneity,
differences in the endpoints measured and variability in the
definition of ‘response’, among other factors. Fundamental
differences in study design, such as the use of a placebo lead-
in period and the timing of baseline assessments, duration of
treatment and inclusion of additional supportive treatment
can also affect study outcomes. Recognising these difficulties,
the UK National Health Service is funding the THREAD
(threshold for antidepressants) study, which compares the
effectiveness of selective serotonin re-uptake inhibitors
(SSRIs) plus supportive care with supportive care alone in
primary care patients with HAMD scores  12 (40).
In this study, we defined ‘milder depression’ as a HAMD17
score of 15–18. Because there is no ‘definitive’ or universally
accepted definition of milder depression in terms of a range
of scores on the HAMD17, the range of 15–18 was selected
as it is consistent with that used in other published work to
represent ‘mild’ depression (34,36,38). We used the
HAMD17 to assess depression, because ‘‘although its limita-
tions are well documented (41)’’, it remains the gold standard
for evaluating the efficacy of new treatments (41–43).
It is unlikely that improved HAMD17 scores in our study
were related to pharmacological effects of duloxetine
unrelated to antidepressant activity. While it is true that an
antidepressant with a predominantly sedative pharmacological
profile might improve HAMD17 scores relating to insomnia
by virtue of its sedative effects alone, duloxetine does not
cause sedation in the vast majority of patients. Data to sup-
port this contention come from adverse event reporting,
where insomnia reported as an adverse event occurred at
least as often (in 12.0% of patients) as somnolence (in
10.7% of patients). Further, duloxetine is in fact associated
with anorexia and weight loss with short-term treatment
rather than increased appetite and/or weight gain (32),
strongly suggesting that increased appetite resulting from
pharmacological effects of duloxetine is not driving an
improvement on the HAMD weight and appetite item (44).
A limitation of this study is that patients in our analysis
population had baseline HAMD17 scores of 15–18, indicative
of milder depression, and CGI-S scores of  4, 4 being
indicative of ‘moderate’ depression (29). One explanation
for this discrepancy might be that the HAMD17 is a multi-
dimensional instrument which yields an overall severity score
via the summation of ratings on a selection of items relating
to individual depressive symptoms. By contrast, with the
CGI-S, the clinician is required to arrive at an overall, global
assessment of the patient’s disease severity. While a particu-
larly severe symptom would not unduly load the final out-
come on the HAMD17 as it would be ‘watered down’ by a
lower level of severity of other symptoms rated by the
HAMD17, the final outcome on the CGI-S might be dispro-
portionately driven by one particularly severe symptom,
which would lead to a disconnect between ratings on these
two instruments. We would argue that by being a more
representative measure of the individual symptoms making
up the syndrome of depression, the total score on the
HAMD17 carries more weight than the one-item CGI-S,
although both have their place.
A further limitation is that this is a post-hoc analysis of
pooled data from a subgroup of patients from two separate
trials. These studies were only 9 weeks in duration, and even
patients with milder depression would be expected to be
treated for longer periods. Both studies excluded patients
with comorbid mental health and severe physical problems,
and these are highly prevalent in everyday primary care.
In conclusion, duloxetine 60 mg once daily was effective in
the treatment of patients with milder MDD, and the safety
and tolerability of duloxetine in this population were consis-
tent with that seen overall in the two published studies from
which the subset of patients with milder MDD included in
this analysis were taken (19,20). The lack of a demonstrably
higher rate of discontinuation due to adverse events in the
duloxetine-treated patients in this milder MDD population
compared with that in the overall population in the two
published studies suggests that patients with milder MDD
are not less tolerant of duloxetine treatment than patients
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with other published data in patients with milder MDD
described previously, are at odds with guidance advising
against the use of antidepressants in milder depression. This
disparity may be driven by a lack of clarity within such
guidelines as to what constitutes milder depression, which
itself reflects the confusion and lack of consensus regarding
the terminology currently used to describe milder depressive
states as a whole.
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